OUR PIPELINE
A focused and expandable platform.
DISCOVERY
PRECLINICAL
p1
p2
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Lead: TBC-1
Resectable NSCLC
Next Gen Programs
Multiple Indications
Platform Extensions
Undisclosed
BIOPSY-TO-ACTION
From biopsy to patients.
We are advancing a clear, focused development path to bring TBC-1 to patients, starting with solid tumors where the biology, clinical need, and translational rationale are strongest.
DEFINE
Lock the product and workflow.
DEVELOP
Build the IND-enabling package.
VALIDATE
Learn from paired tissue, blood, and outcomes.
EXPAND
Use a repeatable architecture across indications.
LEAD PROGRAM
TBC-1: A personalized approach for All solid tumors.
TBC-1 is Tidewave's allogeneic, gene-enhanced antigen-presenting cell product. It is designed to be manufactured and cryopreserved in advance, then personalized near or at the point of care using material prepared from the patient's own tumor biopsy
Off-the-shelf backbone
A centrally prepared allogeneic product.
Tumor-informed personalization
The patient's tumor material provides the biological input
Broad immune rationale
Whole-tumor antigen presentation plus CXCL9/10-enhanced immune recruitment.
KEY MILESTONES
Near-term priorities.
NOW
FDA INTERACT completed
YEAR 1
Pre-IND filing
YEAR 2-3
IND filing
YEAR 3-4
Early Phase 1/2a signal, RMAT filing
YEAR 4-5
Phase 2b
Year 6-8
Expansion opportunities
One biopsy could do more.
